Gaucher disease status and treatment assessment: pilot study using magnetic resonance spectroscopy bone marrow fat fractions in pediatric patients
- PMID: 32120306
- DOI: 10.1016/j.clinimag.2020.02.009
Gaucher disease status and treatment assessment: pilot study using magnetic resonance spectroscopy bone marrow fat fractions in pediatric patients
Abstract
Objective: To assess magnetic resonance spectroscopy (MRS) bone marrow fat fractions' ability to discern between untreated Gaucher disease patients and healthy controls based on assessment of bone marrow infiltration and evaluate response to enzyme replacement therapy (ERT) on serial imaging.
Methods: This retrospective case-controlled study compared conventional MRI and bone marrow MRS findings in six pediatric and young adult Gaucher disease patients with age- and sex-matched controls, examining femoral neck and lumbar spine bone marrow fat fractions and bone marrow burden (BMB) scores. Separate analysis of six patients with serial imaging on ERT was performed with analysis of fat fractions, BMB scores, organ volumes, and serum chitotriosidase.
Results: Untreated patients had significantly lower femoral and lumbar spine fat fractions than controls (0.32 versus 0.67, p = 0.041 and 0.17 versus 0.34, p = 0.041, respectively). Total BMB scores were significantly higher in patients (8.0 versus 3.5, p = 0.015). In patients on ERT with average follow-up of 3.5 years, femoral neck fat fraction was the sole significant predictor of treatment duration (R square: 0.804, p < 0.001) when adjusted for age. Femoral neck fat fraction also correlated with lumbar spine fat fraction, liver volume and chitotriosidase (p < 0.05). MRS test-retest reliability was excellent (Pearson correlations: 0.96, 0.99; p-values <0.001). BMB inter-rater reliability was good overall with an intra-class correlation coefficient of 0.79 for total score, although lumbar spine score reliability was poor at 0.45.
Conclusion: MRS-derived bone marrow fat fractions appear capable of detecting Gaucher disease severity and monitoring treatment-related changes as a predictor of ERT duration in pediatric and young adult patients.
Keywords: Bone marrow burden scoring; Bone marrow imaging; Enzyme replacement therapy; Fat fraction; Gaucher disease; Magnetic resonance spectroscopy.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest CF has received consulting fees and/or honoraria from Genzyme corporation, Pfizer Inc., and Shire Pharmaceutical, makers of therapies for Gaucher disease. DJ received a research grant from Genzyme corporation for prior research on Gaucher disease. The remaining authors declare that they have no competing interests.
Similar articles
-
Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience.Radiology. 2003 Nov;229(2):554-61. doi: 10.1148/radiol.2292020296. Epub 2003 Oct 2. Radiology. 2003. PMID: 14526090
-
Quantification of Bone Marrow Involvement in Treated Gaucher Disease With Proton MR Spectroscopy: Correlation With Bone Marrow MRI Scores and Clinical Status.AJR Am J Roentgenol. 2015 Jun;204(6):1296-302. doi: 10.2214/AJR.14.13563. AJR Am J Roentgenol. 2015. PMID: 26001241 Clinical Trial.
-
Fat fraction quantification of bone marrow in the lumbar spine using the LiverLab assessment tool in healthy adult volunteers and patients with Gaucher disease.Intern Med J. 2023 Jul;53(7):1163-1169. doi: 10.1111/imj.15858. Epub 2022 Sep 14. Intern Med J. 2023. PMID: 35762150
-
Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients.Curr Med Res Opin. 2006 Jun;22(6):1045-64. doi: 10.1185/030079906X104623. Curr Med Res Opin. 2006. PMID: 16846538 Review.
-
Imaging and quantifying skeletal involvement in Gaucher disease.Br J Radiol. 2002;75 Suppl 1:A13-24. doi: 10.1259/bjr.75.suppl_1.750013. Br J Radiol. 2002. PMID: 12036829 Review.
Cited by
-
Clinical Outcomes and Genetic Mutations in Turkish Patients with Type 1 Gaucher Disease: Insights from a Single-Center Study.J Pers Med. 2025 Mar 12;15(3):109. doi: 10.3390/jpm15030109. J Pers Med. 2025. PMID: 40137425 Free PMC article.
-
Advances in Bone Marrow Imaging: Strengths and Limitations from a Clinical Perspective.Semin Musculoskelet Radiol. 2023 Feb;27(1):3-21. doi: 10.1055/s-0043-1761612. Epub 2023 Mar 3. Semin Musculoskelet Radiol. 2023. PMID: 36868241 Free PMC article.
-
Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases.Pharmaceuticals (Basel). 2021 Jan 30;14(2):109. doi: 10.3390/ph14020109. Pharmaceuticals (Basel). 2021. PMID: 33573213 Free PMC article. Review.
-
Advantages of digital technology in the assessment of bone marrow involvement in Gaucher's disease.Front Med (Lausanne). 2023 May 12;10:1098472. doi: 10.3389/fmed.2023.1098472. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37250646 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical